The Bixby Center for Global Reproductive Health - Annual Research Day Conference

比克斯比全球生殖健康中心 - 年度研究日会议

• 批准号: 9349057
• 负责人: Joelle Morgan Brown
• 金额: $ 7.09万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-01 至 2018-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9349057
• 关键词: AIDS clinical trial group; AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Adherence; Adolescent; Adolescent and Young Adult; Adult; Affect; African; Anti-Retroviral Agents; Behavioral; California; Clinical; Clinical Trials Unit; Collaborations; Communities; Consultations; Country; Effectiveness; Epidemic; Funding; Future; Goals; HIV; HIV Infections; HIV Vaccine Trials Network; HIV prevention trials network; Individual; Infection; International; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Intervention; Leadership; Measurement; Microbicide Trials Network; Mission; National Institute of Allergy and Infectious Disease; Oral; Peer Review; Persons; Policies; Policy Maker; Population; Positioning Attribute; Prevention; Prevention strategy; Preventive Intervention; Public Health; Reproductive Health; Research; Research Personnel; San Francisco; Science; Series; Source; Southern Africa; Trust; Tuberculosis; United States National Institutes of Health; Universities; Woman; Work; Zimbabwe; aged; dissemination research; experience; innovation; outreach; posters; programs; research data dissemination; standard of care; success; successful intervention; symposium; treatment strategy; trend; virology; young woman

Project Summary The University of Zimbabwe-University of California San Francisco (UZ-UCSF) Collaborative Research Programme is proposing an annual two-day HIV conference in Harare, Zimbabwe to build local and regional capacity to address critical public health challenges that underpin the success of HIV prevention and treatment strategies. UZ-UCSF conducts cutting-edge research on HIV prevention and treatment in Zimbabwe. As a Clinical Trials Unit (CTU; PI Chirenje) of the National Institutes of Health (NIH), the UZ-UCSF Programme collaborates with five NIH-sponsored HIV/AIDS research networks, including the HIV Prevention Trials Network (HPTN), AIDS Clinical Trials Group (ACTG), International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT), HIV Vaccine Trials Network (HVTN), and the Microbicides Trials Network (MTN). For the past 14 years, the UZ-UCSF Programme leadership has conducted a two-day scientific conference where study Investigators and invited speakers present and disseminate new research findings and technical analyses of current trends in HIV and tuberculosis (TB) to 150-200 attendees including key local stakeholders. As a result, the UZ-UCSF Programme is viewed as a valuable technical partner well poised to advise on regional HIV and TB policy and program implementation. The UZ-UCSF Programme aims to expand the scope of the annual conference to include a focus on priority issues related to HIV treatment and biomedical prevention. The scope of work for this proposal supports a series of annual conferences over a 4-year period, through the end of the current CTU funding cycle (11/30/2020). For the 2017 conference (Year 1), we propose to focus on the critical issue of adherence to HIV treatment and prevention with a special focus on adolescent and young African women. Low adherence has been identified as a threat to the regional goal of achieving sustained virological suppression in 90% of infected persons and reducing new infections especially among adolescent and young women. Despite successes in reducing HIV, the sub-Saharan African region continues to have the most serious HIV and AIDS epidemic in the world with roughly 1.5 million new HIV infections per year. While the majority of new HIV infections in the region occur in adults, HIV disproportionately affects young women; more than 4 in 10 new infections among women are in young women aged 15-24. In alignment with the scientific mission of NIAID, the aims of the 2017 conference will be to 1) discuss state-of-the-science evidence on adherence, including successful interventions, with a focus on unique challenges to key populations, such as young African women; 2) identify new research directions related to adherence, including its measurement, influencing factors, needs of key populations; and 3) provide a forum for discussions of adherence to real world implementation of behavioral and clinical interventions. In so doing, the conference will be unique in its approach to build local and regional capacity to address a critical public health challenge that underpins the success of both HIV treatment and prevention strategies.

项目摘要 津巴布韦大学-加州大学弗朗西斯科分校（UZ-UCSF）合作研究 该方案提议每年在津巴布韦的哈拉雷举行为期两天的艾滋病毒会议， 应对关键公共卫生挑战的能力，这些挑战是艾滋病毒预防和治疗取得成功的基础 战略布局UZ-UCSF在津巴布韦进行艾滋病毒预防和治疗的前沿研究。作为 美国国立卫生研究院（NIH）临床试验部门（CTU; PI Chirenje），UZ-UCSF项目 与五个NIH赞助的艾滋病毒/艾滋病研究网络合作，包括艾滋病毒预防试验 网络（HPTN），艾滋病临床试验组（ACTG），国际妇幼青少年艾滋病临床 试验组（IMPAACT），艾滋病毒疫苗试验网络（HVTN）和杀微生物剂试验网络（MTN）。为 在过去的14年里，UZ-UCSF计划领导层举行了为期两天的科学会议， 研究人员和特邀演讲者介绍和传播新的研究成果和技术 向150-200名与会者，包括当地主要利益攸关方，提供艾滋病毒和结核病当前趋势分析。 因此，UZ-UCSF计划被视为一个有价值的技术合作伙伴，随时准备提供建议， 区域艾滋病毒和结核病政策和方案的实施。UZ-UCSF计划旨在扩大范围 将重点放在与艾滋病毒治疗和生物医学有关的优先问题上， 预防本提案的工作范围支持在四年期间举行一系列年度会议， 到当前CTU资助周期结束（2020年11月30日）。对于2017年会议（第1年），我们建议 重点关注坚持艾滋病毒治疗和预防这一关键问题， 青少年和年轻的非洲妇女。遵守率低被认为是对区域目标的威胁， 在90%的感染者中实现持续的病毒学抑制， 在青少年和年轻女性中。尽管在减少艾滋病毒方面取得了成功， 中国仍然是世界上艾滋病毒和艾滋病流行最严重的国家，大约有150万新的艾滋病毒感染者 每年感染。虽然本区域大多数新的艾滋病毒感染发生在成年人中， 对年轻妇女的影响尤为严重;每10名新感染妇女中就有4名以上是年轻妇女 年龄15-24岁。与NIAID的科学使命相一致，2017年会议的目标将是1） 讨论关于依从性的最新科学证据，包括成功的干预措施，重点是独特的 对关键人群的挑战，如非洲年轻妇女; 2）确定新的研究方向， 遵守情况，包括衡量标准、影响因素、关键人群的需求; 3）提供论坛 以讨论遵守行为和临床干预的真实的世界实施。在这样做时， 会议将以独特方式建立地方和区域能力， 这是艾滋病毒治疗和预防战略取得成功的基础。